GE Aerospace Stock Price, News & Analysis

GE Digital has partnered with Alliance Airlines to implement its Fuel Insight™ solution, aiming to enhance fuel efficiency and reduce costs and carbon emissions. This collaboration builds on their existing use of Safety Insight™ and enables Alliance Airlines to leverage data for actionable insights, leading to improved operational efficiency. The airline operates 58 aircraft and plans to add 17 more in 2022, focusing on charter and wet-lease services across Australia. This partnership signifies a strategic move to optimize resources and reduce the airline's CO₂ footprint.

GE Digital has launched its Effective Inertia Metering & Forecasting solution for the National Grid ESO, enhancing the management of grid stability amid increasing renewable energy sources. This technology enables real-time measurement of grid inertia, crucial for maintaining operational reliability when generators disconnect. The deployment leverages machine learning and analytics to inform operational decisions and long-term investments, ultimately supporting a greener energy network. The collaboration is part of a staged delivery approach, ensuring adaptive implementation and successful system integration.

GE Current, a Daintree company, has appointed Arctic Sales to represent its LED lighting and controls solutions for DOT and municipality applications in Alaska. Arctic Sales, with over 25 years of experience in lighting, will also manage Hubbell’s C&I Lighting business, following Current's acquisition in February. This partnership aims to provide seamless service in the growing lighting market, leveraging Arctic Sales' knowledge to adapt to evolving technologies. The collaboration seeks to enhance the roadway lighting sector in Alaska, benefiting both companies.

GE Healthcare has received FDA pre-market approval for its End-tidal (Et) Control software, enhancing general anesthesia delivery through precise oxygen and anesthetic agent targets. This software, previously available in Europe since 2010, is now the sole FDA-approved product of its kind in the U.S. It significantly reduces greenhouse gas emissions by up to 44% and operating room costs by 27%, while improving workflow efficiency. Annually, over 300 million surgeries necessitate general anesthesia, costing around $1.2 billion. The software will be available with the Aisys CS2 Anesthesia Delivery System in the coming months.

GE Aviation recently marked a significant milestone by achieving 400 million flight hours and 37 years of on-time delivery for its navigation database (NDB), serving over 14,000 aircraft globally. The NDB, tailored for each customer, includes more than 18,000 airports and offers 24/7 support. GE's advanced flight management systems (FMS) enhance operational efficiency and situational awareness for airlines. This achievement underscores GE's commitment to delivering reliable aviation solutions and continuous advancements in flight management technology.

The U.S. Air Force and GE initiated Phase 2 testing of the XA100 adaptive cycle engine on March 25, 2023, at the Arnold Engineering Development Complex. This engine is significant for the F-35’s future, having completed Phase 1 in November 2021. The XA100 includes innovations that enhance thrust by over 10% and fuel efficiency by 25%, while also being compatible with Sustainable Aviation Fuel. GE Edison Works oversees the development of this ground-breaking engine, which aims to reduce operational costs and ensure enhanced combat capabilities for the F-35.

GE Renewable Energy has unveiled the world's first 420 kV, 63 kA g³ gas-insulated substation (GIS) circuit-breaker prototype. This innovation marks a significant advancement in the power industry, offering a viable alternative to SF₆ gas. The g³ technology reduces greenhouse gas emissions by over 99%, contributing to cleaner electrical grids. The prototype, showcased to European transmission utilities, is expected for commercial release in 2023. This move aligns with GE's commitment to accelerating grid decarbonization through innovative solutions.

GE Healthcare has initiated a Phase III clinical trial for a new PET radiopharmaceutical aimed at aiding the evaluation of adult patients with suspected Parkinsonian syndromes. This trial follows the success of DaTscan, a leading SPECT agent, to enhance diagnostic imaging options. The study, taking place in France, compares PET technology's higher resolution against SPECT for better visualization of dopamine transporters. Additionally, a SPECT agent study will begin in the U.S. This expansion supports GE's commitment to improving patient care and aligns with the growing need for Parkinson’s disease diagnostics.